Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 first-line regorafenib + nivolumab for unresectable hepatocellular carcinoma
KCT0004867Phase 2Not yet recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of regorafenib, nivolumab in hepatocellular carcinoma (HCC), sponsored by Ono Pharmaceutical. Planned start May 2020; status: not yet recruiting.
02
Drugs
regorafenibnivolumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on KCT0004867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004867.